“If we focus more on the patient and keeping the patient in the center, and doing what's right from the start, then that puts us on the best trajectory to solve some of the problems that we have,” she said.ĭeciding whether to join the EOM would be monumental enough if it was the only major action coming from CMS, but it’s not. Retaining the patient-centered approach that the OCM promoted is key, Rainey said. A major consideration for taking part in the EOM, Skelton said, is “If youdon’t do it, you’re going to be left behind.” The cultural change achieved over 6 years in the OCM was hard won, and no practice wants to backslide, the panelists agreed. And yet, as the panelists explained, not joining the EOM carries its own risk, as many believe that CMS will someday make risk-based reimbursement mandatory thus, time spent in the EOM will be a worthwhile investment. Those on hand have many concerns, but chief among them is the EOM requirement to take on downside risk form the outset-something that the OCM did not do. Rainey and other at the COA meeting say participation agreements that were anticipated weeks ago from CMMI have yet to materialize, making it hard for practices to know what they are agreeing to do if they want to proceed. Skelton, MD, an oncologist with Blue Ridge Cancer Care, based in Roanoke, Virginia. Strickland, a value-based care consultant Anne Marie Rainey, MSN, RN, CHC, director of quality and value-based care for Clearview Cancer Institute, based in Anniston, Alabama and Matthew R. This was especially true among those who spent years fine-tuning their performance in the OCM, which for 6 years was Medicare’s chief way for oncologists take part in an alternative payment model under the 2015 Medicare Access and CHIP Reauthorization Act.īut as the July 1, 2023, EOM implementation date nears, questions remain, and Alberto and her fellow panelists explored many of them.
When the EOM was presented in late June 2022, many practices had hoped by this point they would be saying "yes" to the model. That summed up the sentiment about the EOM among oncologists and practice administrators attending this week’s COA meeting. How many had applied to take part in the Enhancing Oncology Model (EOM)?įinally, how many were planning to join the EOM if they received a participation agreement from the Center for Medicare and Medicaid Innovation (CMMI)? How many in the room had taken part in the Oncology Care Model (OCM)? To open Thursday’s discussion on payment reform at the Community Oncology Alliance (COA) 2023 Community Oncology Conference, moderator Judith Alberto, MHA, RPh, BCOP, COA’s director of Clinical Initiatives, asked several times for a show of hands.
0 kommentar(er)
